title: Development of aseptic subcutaneous abscess after tocilizumab therapy in a patient with SAPHO syndrome complicated by amyloid A amyloidosis.
authors.affiliation: Department of Rheumatology, Kawasaki Medical School, Okayama, Japan.
authors.forename: Shunichi
authors.initials: S
authors.lastname: Fujita
authors.affiliation: Department of Rheumatology, Kawasaki Medical School, Okayama, Japan.
authors.forename: Nami
authors.initials: N
authors.lastname: Kosaka
authors.affiliation: Department of Rheumatology, Kawasaki Medical School, Okayama, Japan.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Mito
authors.affiliation: Department of Dermatology, Kawasaki Medical School, Okayama, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Hayashi
authors.affiliation: Department of Rheumatology, Kawasaki Medical School, Okayama, Japan.
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Morita
mesh_terms: D000038:Abscess / Q000209:etiology / Q000503:physiopathology*; D020083:Acquired Hyperostosis Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000368:Aged; D000686:Amyloidosis / Q000175:diagnosis* / Q000628:therapy; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D035583:Rare Diseases; D051437:Renal Insufficiency / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D018570:Risk Assessment; D000685:Serum Amyloid A Protein / Q000378:metabolism; D012720:Severity of Illness Index; D012871:Skin Diseases / Q000209:etiology / Q000503:physiopathology*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000685:Serum Amyloid A Protein; C502936:tocilizumab